Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Pharmiweb.com RSS Feed PharmiWeb Candidate Blog

Pharmiweb.com RSS Feed PharmiWeb Client Blog

Advertising

Press Releases

365 Press Releases
DateTitleCompany
20 Aug 15 New data show Spiolto® Respimat® provides meaningful quality of life improvements in COPD Boehringer Ingelheim ,
Published by
Pharmiweb.com
19 Aug 15 CHMP recommends label update for Giotrif® with addition of data demonstrating overall survival benefit for patients with EGFR mutation-positive lung cancer Boehringer Ingelheim,
Published by
Business Wire
17 Aug 15 New data show Spiolto® Respimat® provides meaningful quality of life improvement in COPD Boehringer Ingelheim,
Published by
Business Wire
17 Aug 15 New data show Spiolto Respimat provides meaningful quality of life improvements in COPD Boehringer Ingelheim,
Published by
Business Wire
12 Aug 15 Boehringer Ingelheim and Circuit Therapeutics announce new collaboration to discover novel medicines for obesity Boehringer Ingelheim ,
Published by
Pharmiweb.com
06 Aug 15 Boehringer Ingelheim experiences slight growth in local currency terms in the first half of 2015 Boehringer Ingelheim ,
Published by
PharmiWeb.com
01 Aug 15 Boehringer Ingelheim Statement on Agreement to Sell Roxane to Hikma Pharmaceuticals PLC Boehringer Ingelheim ,
Published by
PharmiWeb.com
01 Aug 15 First U.S. Patients Enroll in Boehringer Ingelheim’s Global RE-DUAL PCI™ and RE-CIRCUIT™ Trials Evaluating Pradaxa® (dabigatran etexilate mesylate) Boehringer Ingelheim ,
Published by
PharmiWeb.com
28 Jul 15 Boehringer Ingelheim enters into an exclusive license agreement with Hanmi Pharmaceutical to develop 3rd generation EGFR targeted therapy in lung cancer Boehringer Ingelheim ,
Published by
PharmiWeb.com
28 Jul 15 Boehringer Ingelheim enters into an exclusive license agreement with Hanmi Pharmaceutical to develop 3rd generation EGFR targeted therapy in lung cancer Boehringer Ingelheim,
Published by
Business Wire
25 Jul 15 MHRA review confirms benefit/risk profile of Alteplase - the only licensed clot buster for acute ischaemic stroke Boehringer Ingelheim ,
Published by
PharmiWeb.com
24 Jul 15 MHRA review confirms benefit/risk profile of Alteplase - the only licensed clot buster for acute ischaemic stroke Boehringer Ingelheim,
Published by
Business Wire
16 Jul 15 Boehringer Ingelheim Welcomes the Inclusion of OFEV® (nintedanib*) in the Updated International Treatment Guidelines for Idiopathic Pulmonary Fibrosis (IPF) Boehringer Ingelheim ,
Published by
PharmiWeb.com
15 Jul 15 Boehringer Ingelheim Welcomes the Inclusion of OFEV® (nintedanib*) in the Updated International Treatment Guidelines for Idiopathic Pulmonary Fibrosis (IPF) Boehringer Ingelheim,
Published by
Business Wire
08 Jul 15 Phase III data published in The Lancet Oncology shows a significant overall survival benefit of Giotrif® (afatinib) compared to Tarceva® (erlotinib) Boehringer Ingelheim ,
Published by
PharmiWeb.com
08 Jul 15 Phase III data published in The Lancet Oncology shows a significant overall survival benefit of Giotrif® (afatinib) compared to Tarceva® (erlotinib) in patients with previously treated advanced squamous cell carcinoma of the lung Boehringer Ingelheim ,
Published by
PharmiWeb.com
06 Jul 15 Phase III data published in The Lancet Oncology shows a significant overall survival benefit of Giotrif® (afatinib) compared to Tarceva® (erlotinib) in patients with previously treated advanced squamous cell carcinoma of the lung Boehringer Ingelheim ,
Published by
PharmiWeb.com
06 Jul 15 Phase III data published in The Lancet Oncology shows a significant overall survival benefit of Giotrif® (afatinib) compared to Tarceva® (erlotinib) (...) Boehringer Ingelheim,
Published by
Business Wire
03 Jun 15 NICE recommends VARGATEF® (nintedanib*) in combination with docetaxel as an option for patients with non-small cell lung cancer of adenocarcinoma histology within its licensed indication Boehringer Ingelheim,
Published by
Business Wire
01 Jul 15 Boehringer Ingelheim Animal Health: 2015 European PRRS Research Award open for submissions until July 31st Boehringer Ingelheim ,
Published by
PharmiWeb.com
08 Jun 15 Type 2 diabetes: Patients reporting better quality of communication by their physician show improved self-care Boehringer Ingelheim ,
Published by
PharmiWeb.com
08 Jun 15 Type 2 diabetes: Empagliflozin/metformin demonstrates reductions in blood glucose in data presented at ADA Boehringer Ingelheim ,
Published by
PharmiWeb.com
22 Jun 15 Idarucizumab* reverses the anticoagulant effect of dabigatran within minutes in patient study Boehringer Ingelheim,
Published by
PharmiWeb.com
02 Jul 15 New advance in COPD maintenance treatment, Spiolto® Respimat®, approved in first European countries   Boehringer Ingelheim,
Published by
Business Wire
02 Jul 15 New advance in COPD maintenance treatment, Spiolto® Respimat®, approved in first European countries Boehringer Ingelheim ,
Published by
PharmiWeb.com
16 Jun 15 New publication in The Lancet describes effective reversal of Pradaxa® in healthy volunteers Boehringer Ingelheim GmbH,
Published by
Business Wire
08 Jun 15 Type 2 diabetes: Patients reporting better quality of communication by their physician show improved self-care Boehringer Ingelheim,
Published by
Business Wire
08 Jun 15 Type 2 diabetes: Empagliflozin/metformin demonstrates reductions in blood glucose in data presented at ADA Boehringer Ingelheim,
Published by
Business Wire
16 Jun 15 New publication in The Lancet describes effective reversal of Pradaxa® in healthy volunteers Boehringer Ingelheim,
Published by
PharmiWeb.com
22 Jun 15 Idarucizumab* reverses the anticoagulant effect of dabigatran within minutes in patient study Boehringer Ingelheim,
Published by
Business Wire
Advertising
Share | | |
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.